|
Mission
To research and mine the rich pharmaceutical, nutraceutical and cosmeceutical potential from pomegranates and to promote their organic cultivation to increase their value.
Technology
Fermentation of pomegranate juice and aerial parts aqueous extracts,, and blending of these fermented products with pomegranate seed oil.
History
Founded in 1999 at the Technion Incubator Company (TEIC), a subsidiary of the Technion-Israel Institute of Technology, Haifa, Israel.
Future
Drug discovery and design, complex botanical drugs.
Punisyn Pharmaceuticals, Ltd.
Phytaceutical pipeline
Punisyn-1, oil-in-oil emulsion packaged in soft gel capsules for oral therapy and prevention of prostate cancer, ovarian cancer, breast cancer by anti-inflammatory, anti-anigogenic, pro-differentiating, anti-invasive , hormone-modulating mechanisms..
Fi-01, oil-in-oil emulsion containing aqueous originating and lipid originating fractions from an alternative plant source, for complementary therapy of all cancers, by promoting differentiation.
Plant synergy
The whole may be more than the sum of its parts. Synergy between plant parts can be customized and measured with individual plants, and / or between individual plants.
Strategic partnerships
Punisyn seeks partners from the pharmaceutical sector to help finance the completion of drug development and to negotiate eventual marketing and sales.
INVESTORS:
opportunity
The company is poised to introduce a new type of drug into the market with a minimum turn around time because of the low toxicity profile and origin of the drug in a common food. The application would be as a non-toxic cancer treatment.
benefits
Early entry could be followed by early exit strategy, once Stage 1 and 2 clinical trials are complete and acquisition of merger with a major pharmaceutical partner. Other benefits include the satisfaction from working with Nature and relieving human suffering.
|
|
POMEGRANATE
EMULSION
Research Reagent
The pomegranate emulsion is produced in an Israel Ministry of Health approved facility under GMP and ISO 9001 conditions and kosher supervision. All pomegranate ingredients used are from organically certified trees and their fruit.
The product is extremely low in only the natural sugars of the pomegranate, and most of these have been removed. No sweeteners of any kind have been added. The product comes in a 150 ml sealed, new, clear glass bottle. It should be kept in a cool dark place, and refrigerated after opening. The recommended daily dose as a dietary supplement is from 1-6 teaspoons per day. Patients taking medications, pregnant and nursing women, and children should consult a physician before use.
Rimonest is interested in cooperative research with qualified investigators and invites inquiries.
Synergy
The product, an oil-in-water (o-w) emulsion is available for research purposes. It is the first generation of a nutriment that will eventually be developed into an oil-in-oil (o-o) emulsion combining the "fatty part of the wine" with the seed oil. The present o-w emulsion is aimed, based on in vitro studies, to maximize the product's inherent bio-active synergy.
Pleiotropy
Pleiotropic traditionally refers to an effect mediated in multiple physiological organ systems from a single genetic focus. Here, pleiotropic is used in a novel sense (Newman and Lansky, 2007, Pomegranate: The Most Medicinal Fruit, Laguna Beach, California, Basic Books), as the interaction between the mammal and the plant produces mammalian effects at multiple levels and in multiple organs.
NO CLAIMS
This is an experimental product for research. No specific health claims are made for its use in human beings.
The product has not been approved by the U.S. Food and Drug Administration and is not intended for the treatment or prevention of disease.
SAFETY
This is a natural product with an expected very low toxicity profile. First encounters with any botanical product should include spot allergy checks by placing a small amount on the skin and waiting an hour, followed by a second, ingestion of a tiny amount and waiting 24 hours to observe and record the reaction. Severe allergic reactions to pomegranate fruit are rare, but not unknown. A full Material and Safety Data Sheet (MSDS) of the o-w emulsion is available. If any problems are experienced from contact with this product, consult a physician..
ORDERING
Pomegranate Emulsion, reagent for research. 150 ml in a sealed clear glass bottle.
Per bottle: $100.
Express shipping included. Pre-payment required.
Funds can be transferred by Western Union (inquire for details) or SWIFT transfer to the coordinates below.
Name on account: Rimonest Ltd.
Bank: Leumi, Bank number: 10
Branch: Horev, Address: Horev 16, Haifa, Israel
Branch number: 880 Account number: 113500/90
SWIFT code: LUMIILIT
Be sure to fax confirmation from bank for transfer, and also send email to confirm order.
CONTACT
Email: info@rimonest.com
Fax: +972 3 521 4728
Cell phone for limited use:
+972 545 273 156 (no messages please)
Post: POB 9945, Haifa, Israel
Tele-medical Consultation
Ephraim Philip Lansky, M.D. is a licensed medical doctor in Israel with a quarter century clinical experience in the use of classical homeopathy, medicinal foods and mind-body medicine. He is available by telephone to consult on all medical conditions. Inquire by email with a short clinical summary or to schedule an appointment.
|
|
|
Publications
Schubert, S.Y., Lansky, E.P., Neeman, I., 1999. Antioxidant and eicosanoid enzyme inhibition properties of pomegranate seed oil and fermented juice flavonoids. Journal of Ethnopharmacology, 66, 11-7.
Kim, N.D., Mehta, R., Yu, W., Neeman, I., Livney, T., Amichay, A., Poirier, D., Nicholls, P., Kirby, A., Jiang, W., Mansel, R., Ramachandran, C., Rabi, T., Kaplan, B., Lansky E., 2002. Chemopreventive and adjuvant therapeutic potential of pomegranate (Punica granatum) for human breast cancer. Breast Cancer Research and Treatment 71, 203-17.
Hora, J.J., Maydew, E.R., Lansky, E.P., Dwivedi, C., 2003. Chemopreventive effects of pomegranate seed oil on skin tumor development in CD1 mice. Journal of Medicinal Food 6, 157-61.
Toi, M., Bando, H., Ramachandran, C., Melnick, S.J., Imai, A., Fife, R.S., Carr, R.E., Oikawa, T., Lansky, E.P., 2003. Preliminary studies on the anti-angiogenic potential of pomegranate fractions in vitro and in vivo. Angiogenesis 6, 121-8.
van Elswijk, D.A., Schobel, U.P., Lansky, E.P., Irth, H., van der Greef, J., 2004. Rapid dereplication of estrogenic compounds in pomegranate (Punica granatum) using on-line biochemical detection coupled to mass spectrometry. Phytochemistry 65, 233-41.
Kawaii, S., Lansky, E.P., 2004. Differentiation-promoting activity of pomegranate (Punica granatum) fruit extracts in HL-60 human promyelocytic leukemia cells. Journal of Medicinal Food 7, 13-8.
Mehta, R., Lansky, E.P., 2004. Breast cancer chemopreventive properties of pomegranate (Punica granatum) fruit extracts in a mouse mammary organ culture. European Journal of Cancer Prevention 13, 345-8.
Albrecht, M., Jiang, W.,, Kumi-Diaka, J., Lansky, E.P., Gommersall, L.M., Patel, A., Mansel, R.E., Neeman, I., Geldof, A.A., Campbell, M.J. , 2004. Pomegranate extracts potently suppress proliferation, xenograft growth, and invasion of human prostate cancer cells. Journal of Medicinal Food 7, 274-83.
Lansky, E.P., Jiang, W., Mo, H., Bravo, L., Froom, P., Yu, W., Harris, N.M., Neeman, I., Campbell, M.J., 2005. Possible synergistic prostate cancer suppression by anatomically discrete pomegranate fractions. Investigational New Drugs 23, 11-20.
Lansky, E.P., Harrison, G., Froom, P., Jiang, W.G., 2005. Pomegranate (Punica granatum) pure chemicals show possible synergistic inhibition of human PC-3 prostate cancer cell invasion across Matrigel. Investigational New Drugs 23, 121-2. Erratum in: Investigational New Drugs 2005, 23, 379.
Lansky, E.P., von Hoff, D.D., 2005. Complex and simple. Leukemia Research 29, 601-2.
Aslam, M.N., Lansky, E.P., Varani, J., 2006. Pomegranate as a cosmeceutical source: pomegranate fractions promote proliferation and procollagen synthesis and inhibit matrix metalloproteinase-1 production in human skin cells. Journal of Ethnopharmacology 103, 311-8.
Lansky, E.P., 2006. Beware of pomegranates bearing 40% ellagic acid. Journal of Medicinal Food 9, 119-22.
Lansky, E.P., Newman, R.A., 2007. Punica granatum (pomegranate) and its potential for the prevention and treatment of cancer and inflammation. Journal of Ethnopharmacology 109, 177-206.
Katz, S.R., Newman, R.A., Lansky, E.P., 2007. Punica granatum: Heuristic treatment for diabetes mellitus. Journal of Medicinal Food 10, 213-7.
|
Patents
Lansky, E.P., 1999. Phytoestrogen supplement prepared from pomegranate seeds and a herbal mixture or coconut milk. US Patent, 5,891,440.
Lansky, E.P., 2000. Pomegranate supplements prepared from pomegranate material including pomegranate seeds. US Patent, 6,060,063.
Lansky, E.P., 2003. Pomegranate juice and oil products. South Africa Patent, 2002/3898.
Lansky, E.P., 2004. Pomegranate juice and oil products. Australia Patent, 774619.
Lansky, E.P., 2004. Phytoestrogen supplements. Israel Patent, 149521.
|
|